Royal Bank Of Canada Surface Oncology, Inc. Transaction History

Royal Bank Of Canada

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$0.57 - $0.88 $923 - $1,425	1,620 Added 7.1%	24,432 $21,000
Q1 2023 May 15, 2023	SELL	$0.61 - $1.03 $288 - $487	-473 Reduced 2.03%	22,812 $15,000
Q4 2022 Feb 14, 2023	SELL	$0.62 - $1.21 $76,294 - $148,896	-123,055 Reduced 84.09%	23,285 $19,000
Q3 2022 Nov 14, 2022	BUY	$1.05 - $2.1 $14,533 - $29,066	13,841 Added 10.45%	146,340 $152,000
Q2 2022 Aug 15, 2022	BUY	$1.42 - $3.15 $17,849 - $39,595	12,570 Added 10.48%	132,499 $218,000
Q1 2022 May 16, 2022	BUY	$2.65 - $5.08 $22,731 - $43,576	8,578 Added 7.7%	119,929 $352,000
Q4 2021 Feb 14, 2022	BUY	$4.73 - $7.9 $12,922 - $21,582	2,732 Added 2.52%	111,351 $533,000
Q3 2021 Nov 15, 2021	SELL	$5.16 - $7.98 $14,654 - $22,663	-2,840 Reduced 2.55%	108,619 $822,000
Q2 2021 Aug 16, 2021	BUY	$6.45 - $9.09 $718,910 - $1.01 Million	111,459 New	111,459 $831,000

315K

Ticker SURF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,034,000
Description
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibo...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.